Free · Tool

Bloodwork Panel Planner

Plan consolidated blood work panels based on your peptide research protocol. Get recommended biomarkers, testing frequency, and lab panel suggestions organized by protocol phase — baseline, mid-cycle, and post-cycle.

Select your peptides and protocol phase to generate a consolidated bloodwork panel with reference ranges, cost estimates, and a testing timeline.

1
Select Your Peptides
2
Select Protocol Phase
Baseline
Before starting
Mid-Protocol
4–6 weeks in
Post-Protocol
2–4 weeks after stopping

Bloodwork Panel — Signal IQ

3
Your Consolidated Panel
TestRequired ByReference RangeWhat to WatchEst. Cost
Testing Timeline
General
Male
Female
MarkerNormal RangeUnitNotes
Pulse

Want help interpreting your results? Chat with Pulse, Signal IQ’s free AI research assistant — ask about any biomarker, reference range, or what a change between draws might mean.

Research & educational use only. This planner provides general biomarker and testing-frequency information for peptide research protocols. It is not medical advice, a diagnosis, or a substitute for guidance from a licensed clinician. Reference ranges vary by laboratory — always confirm results with your provider. Signal IQ does not sell peptides.

Frequently Asked Questions

What bloodwork do I need before peptides?
Baseline bloodwork before starting peptides typically includes a Comprehensive Metabolic Panel (CMP), Complete Blood Count (CBC), Lipid Panel, and category-specific markers. GH peptides require IGF-1, GLP-1 agonists need HbA1c and pancreatic enzymes, and hormonal peptides require a full hormone panel including Total/Free Testosterone, Estradiol, LH, FSH, and SHBG. Use the planner above to generate your exact panel based on the peptides you plan to research.
How often should I get blood work on peptides?
Best practice is three phases: Baseline (before starting), Mid-Protocol (4–6 weeks in) to assess response and safety markers, and Post-Protocol (2–4 weeks after stopping) to confirm recovery. Some markers like liver enzymes and blood glucose may warrant more frequent monitoring if abnormalities are detected during the mid-protocol check.
What does IGF-1 tell me about GH peptides?
IGF-1 (Insulin-like Growth Factor 1) is the primary biomarker for assessing growth hormone secretagogue effectiveness. Since GH is released in pulses and has a short half-life, IGF-1 provides a more stable measure of overall GH activity. A rising IGF-1 from baseline indicates the GH peptide is successfully stimulating growth hormone release. Target ranges are typically 200–350 ng/mL for adults, though optimal levels vary by age and individual goals.